Lexicon Pharmaceuticals (LXRX) Research & Development (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Research & Development data on file, last reported at $12.8 million in Q1 2026.

• On a quarterly basis, Research & Development fell 16.64% year-over-year to $12.8 million in Q1 2026; TTM through Mar 2026 was $58.6 million, a 31.42% decrease from a year earlier, with the FY2025 full-year figure at $61.1 million, down 27.65% from the prior year.
• Research & Development for Q1 2026 stood at $12.8 million, up from $11.3 million in the prior quarter.
• Over the last five years, Research & Development for LXRX reached as high as $26.7 million in Q4 2024 and fell as low as $10.6 million in Q3 2022.
• Historically, Research & Development has averaged $15.9 million across 5 years, with a median of $14.8 million in 2023.
• Across the five-year window, Research & Development soared 80.77% in 2024 and slumped 57.6% in 2025, its largest moves.
• Year by year, Research & Development stood at $14.0 million in 2022, then grew by 5.62% to $14.8 million in 2023, then surged by 80.77% to $26.7 million in 2024, then slumped by 57.6% to $11.3 million in 2025, then climbed by 12.74% to $12.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $12.8 million in Q1 2026, $11.3 million in Q4 2025, and $18.8 million in Q3 2025.